Clinical Research Directory
Browse clinical research sites, groups, and studies.
Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Prostate Cancer
Sponsor: Benha University
Summary
This prospective study aims to validate the clinical outcomes of performing a concomitant trans-perineal prostate biopsy and laser ablation (termed "Bioblation") during a single session. The intervention is designed for symptomatic patients presenting with lower urinary tract symptoms (LUTS) who are highly suspected to have low to favorable intermediate-risk prostate cancer. By combining diagnosis and targeted treatment under local anesthesia, this approach seeks to facilitate early relief of severe symptoms and a rapid return to daily activities. Ultimately, the study evaluates whether this combined procedure decreases the patient's exposure to multiple, temporally separated interventions without compromising oncological safety or efficacy.
Official title: Validation of Concomitant Trans-Perineal Prostate Biopsy and Ablation (Bioblation) for Symptomatic (LUTS) Selected Most Probably Low and Intermediate Risk PCa Patients
Key Details
Gender
MALE
Age Range
18 Months - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-04-10
Completion Date
2026-04-28
Last Updated
2026-04-13
Healthy Volunteers
No
Interventions
Bioblation
The procedure is performed under local anesthesia and a prostatic nerve block. Under real-time transrectal ultrasound (TRUS) visualization, four biopsy cores are taken transperineally from each suspected focal lesion, alongside systematic biopsies of the transitional zones. Immediately following the biopsy, 18G Chipa needles are inserted transperineally to pass 300-micron laser fibers to the target site. Using the Elesta system, 7W of laser energy is delivered via MRI-guided cognitive fusion to induce thermal coagulative necrosis of the tumor.
Locations (1)
Urology Department, Benha University Hospitals
Banhā, Qalyubia Governorate, Egypt